{"id":"NCT03276936","sponsor":"Vyne Therapeutics Inc.","briefTitle":"A Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 in the Treatment of Moderate to Severe Papulopustular Rosacea","officialTitle":"An Open-Label Study to Evaluate the Long-Term Safety of Topical Administration of FMX103 for 40 Weeks in the Treatment of Moderate to Severe Facial Papulopustular Rosacea (Study FX2016-13)","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2017-09-05","primaryCompletion":"2019-01-03","completion":"2019-01-15","firstPosted":"2017-09-08","resultsPosted":"2020-12-29","lastUpdate":"2022-01-18"},"enrollment":504,"design":{"allocation":"NA","model":"SINGLE_GROUP","masking":"NONE","primaryPurpose":"TREATMENT"},"conditions":["Papulopustular Rosacea"],"interventions":[{"type":"DRUG","name":"FMX103 1.5%","otherNames":[]}],"arms":[{"label":"Minocycline Foam 1.5%","type":"EXPERIMENTAL"}],"summary":"The primary objective is to show that open-label extended treatment with FMX103 1.5%, for up to an additional 40 weeks, is safe and well tolerated.","primaryOutcome":{"measure":"Absolute Change From Baseline in Inflammatory Lesion Count at Week 40","timeFrame":"Day 0/ Baseline (Final visit of previous DB study [Week 12]) and at Week 40","effectByArm":[{"arm":"DB-FMX103 1.5% Minocycline Foam","deltaMin":23,"sd":10.96},{"arm":"DB-Vehicle Foam","deltaMin":22.5,"sd":10.83}],"pValues":[]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":null,"exclusionCount":null},"locations":{"siteCount":79,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":["http://foamix.co.il/"]},"adverseEventsSummary":{"seriousAny":{"events":9,"n":332},"commonTop":["Sinusitis"]}}